Sélectionner la langue
CD8 alpha
CD8 alpha Informations sur la molécule
| Nom anglais | Cluster of differentiation 8 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 18 | Alias de la cible | CD8 Antigens |
| Phase de R&D la plus avancée | Phase 3 Clinical | ||
| Nom anglais | Cluster of differentiation 8 |
| Alias de la cible | CD8 Antigens |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 18 |
| Phase de R&D la plus avancée | Phase 3 Clinical |
CD8 alpha Liste de produits
- Attribut
Protein (13)
- Bibliothèque de produits
En ligne (13)
- Espèces
Mouse (3)Human (8)Cynomolgus (2)
- Étiquette
His Tag & Avi Tag (4)His Tag (8)Fc Tag (1)
- Marqueur
Biotin-labeled (3)Unconjugated (4)AF488 Labeled (3)AF647 Labeled (1)PE Labeled (1)APC Labeled (1)
Ajouter au panier
Quantité totale13
- 1
- 2
CD8 alphaContexte de la molécule
Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. In NK-cells, the presence of CD8A homodimers at the cell surface provides a survival mechanism allowing conjugation and lysis of multiple target cells. CD8A homodimer molecules also promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells.
CD8 alphaAlias de la molécule
CD8A,CD8,Leu2,MAL,p32
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| 89Zr-Df-crefmirlimab | IAB-22-M2C | Phase 3 Clinical | Imaginab Inc | Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Leukoencephalopathy, Progressive Multifocal; Lymphoma; Melanoma; Multiple Sclerosis; Skin Melanoma; Solid tumours | Details |
| RB-0003 | RB-0003; BNT-111 | Phase 2 Clinical | Biontech Se, Tron | Melanoma | Details |
| CD8+ memory T cell therapy (Stanford University) | Phase 2 Clinical | Stanford University | Leukemia; Leukemia, Myelogenous, Chronic; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
| GEN-009 | GEN-009 | Phase 2 Clinical | Genocea Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck | Details |
| VE-800 | VE-800 | Phase 2 Clinical | Vedanta Biosciences Inc | Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Neoplasm Metastasis; Stomach Neoplasms | Details |
| EBViNT Cell (Eutilex) | Phase 2 Clinical | Eutilex | Lymphoma, Extranodal NK-T-Cell | Details | |
| ZED88082A | ZED88082A | Phase 2 Clinical | Umcg The University Medical Center Groningen | Neoplasm Metastasis; Neoplasms | Details |
| AZD-6750 | AZD6750; AZD-6750 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cystadenocarcinoma, Serous; Melanoma; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | Details |
| AZD-9793 | AZD9793; AZD-9793 | Phase 2 Clinical | Astrazeneca Plc | Carcinoma, Hepatocellular; Neoplasm Metastasis; Solid tumours | Details |
| AZD-5492 | AZD5492 | Phase 2 Clinical | Astrazeneca Plc | Arthritis, Rheumatoid; Leukemia, B-Cell; Lupus Erythematosus, Systemic; Lymphoma, B-Cell; Myositis; Neoplasms | Details |
| SNA-006 | 68-Ga-NODAGA-SNA-006; 68Ga-NODAGA-SNA006; SNA-006 | Phase 2 Clinical | Smartnuclide Biopharma | Neoplasms; Solid tumours | Details |
| NY-ESO-1-specific autologous CD8+ T-cell therapy (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center, National Cancer Institute | Liposarcoma; Sarcoma; Sarcoma, Synovial | Details | |
| MTX-101 (Mozart Therapeutics) | MTX-101 (Mozart Therapeutics) | Phase 1 Clinical | Mozart Therapeutics Inc | Autoimmune Diseases; Diabetes Mellitus, Type 1 | Details |
| [18F]GEH200521 | GEH200521 (18F); GEH-200521 | Phase 1 Clinical | Ge Healthcare | Solid tumours | Details |
| Tcrx T cell Therapy(Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital School Of Zhejiang University School Of Medicine | Gastroesophageal Junction Neoplasms; Stomach Neoplasms | Details | |
| SCRI-E2CAR_EGFRtv1 | SCRI-E2CAR_EGFRtv1 | Phase 1 Clinical | Umoja BioPharma Inc | Osteosarcoma | Details |
| 89Zr-DFO-REGN5054 | 89Zr-DFO-REGN5054 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Solid tumours | Details |
| AGX-148 | AGX-148; AGX148 | Phase 1 Clinical | AgonOx Inc | Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urogenital Neoplasms | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques
Partager vers :